GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Travere Therapeutics Inc (NAS:TVTX) » Definitions » 10-Year RORE %

TVTX (Travere Therapeutics) 10-Year RORE % : 23.88% (As of Sep. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Travere Therapeutics 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Travere Therapeutics's 10-Year RORE % for the quarter that ended in Sep. 2024 was 23.88%.

The industry rank for Travere Therapeutics's 10-Year RORE % or its related term are showing as below:

TVTX's 10-Year RORE % is ranked better than
90.34% of 590 companies
in the Biotechnology industry
Industry Median: -6.205 vs TVTX: 23.88

Travere Therapeutics 10-Year RORE % Historical Data

The historical data trend for Travere Therapeutics's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Travere Therapeutics 10-Year RORE % Chart

Travere Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 7.48 -17.35

Travere Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.77 -17.35 2.62 1.86 23.88

Competitive Comparison of Travere Therapeutics's 10-Year RORE %

For the Biotechnology subindustry, Travere Therapeutics's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Travere Therapeutics's 10-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Travere Therapeutics's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Travere Therapeutics's 10-Year RORE % falls into.



Travere Therapeutics 10-Year RORE % Calculation

Travere Therapeutics's 10-Year RORE % for the quarter that ended in Sep. 2024 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( -4.55-1.19 )/( -24.04-0 )
=-5.74/-24.04
=23.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2024 and 10-year before.


Travere Therapeutics  (NAS:TVTX) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Travere Therapeutics 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of Travere Therapeutics's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Travere Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
3611 Valley Centre Drive, Suite 300, San Diego, CA, USA, 92130
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
Executives
Sandra Calvin officer: VP, Corp Controller and CAO 3611 VALLEY CENTER DRIVE, SUITE 300, SAN DIEGO CA 92130
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Jeffrey A Meckler director 740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
Jula Inrig officer: Chief Medical Officer C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
William E. Rote officer: Senior Vice President, R&D C/O RETROPHIN, INC., 3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Christopher R. Cline officer: Chief Financial Officer C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, STE 300, SAN DIEGO CA 92130
Eric M Dube director, officer: Chief Executive Officer 3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Peter Heerma officer: Chief Commercial Officer C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
Elizabeth E Reed officer: SVP, GC & Corporate Secretary 9050 CAMINO SANTA FE, SAN DIEGO CA 92121
Laura Clague officer: Chief Financial Officer 370 PARK RANCH PLACE, ESCONDIDO CA 92025
Steve Aselage director 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Brinkley Ruth Williams director C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
Noah L. Rosenberg officer: Chief Medical Officer C/O ESPERION THERAPEUTICS, INC., 46701 COMMERCE CENTER DRIVE, PLYMOUTH MI 48170
Suzanne Louise Bruhn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Neil F. Mcfarlane officer: Chief Operating Officer C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130